UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
AMENDMENT NO. 5
on
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): November 26, 2001
XOMA Ltd.
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
BERMUDA
--------------------------------------------------------------------------------
(State or other jurisdiction of incorporation)
0-14710 52-2154066
(Commission File Number) (IRS Employer Identification No.)
2910 Seventh Street, Berkeley, California 94710
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code (510) 204-7200
------------------------------
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 8.01. Other Events
As previously announced on November 26, 2001, XOMA Ltd. ("XOMA") has
entered into a development and license agreement with Millennium
Pharmaceuticals, Inc. ("Millennium").
Under the related investment agreement, Millennium committed to purchase,
at XOMA's option, up to $50 million worth of XOMA common shares over the 30
months following the effective date of the investment agreement, through a
combination of convertible debt and equity at then prevailing market prices. As
previously announced, on May 16, 2003, XOMA and Millennium agreed to delay the
maturity of the convertible debt until February 26, 2004 and to adjust the
timing of Millennium's obligation to purchase the remaining $37.5 million worth
of XOMA common shares. As previously announced, on October 10, 2003, XOMA
announced that it discontinued development of MLNM2201 (formerly known as
LDP-01), one of the two products being developed under its collaboration with
Millennium, which had the effect of reducing Millennium's obligation to purchase
XOMA common shares under the investment agreement by 40% from up to $33.5
million remaining to up to $20.1 million. As previously announced, on February
24, 2004, XOMA and Millennium agreed to delay the maturity of the convertible
debt until April 15, 2004 (or the third business day after the date the related
registration statement is declared effective, if later) and to further adjust
the timing of Millennium's obligation to purchase the remaining $14.7 million
worth of XOMA common shares.
On October 12, 2004, XOMA and Millennium announced the restructuring of
their agreement related to the collaboration for the development of MLN2222,
currently being investigated in a phase I clinical trial for Coronary Artery
Bypass Graft (CABG) surgery. This agreement supersedes the companies' previous
development and investment agreements, established in November, 2001. A copy of
the press release is attached hereto as Exhibit 9 and is incorporated herein by
reference.
Item 9.01. Exhibits
1. Press Release dated November 26, 2001.*
2. Development and License Agreement dated as of November 26, 2001 by and
among Millennium Pharmacueticals Inc., XOMA (US) LLC and XOMA Ireland
Limited (with certain confidential information omitted, which omitted
information is the subject of a confidential treatment request and has been
filed separately with the Securities and Exchange Commission).*
-2-
3. Investment Agreement dated as of November 26, 2001 by and among XOMA Ltd.,
Millennium Pharmaceuticals, Inc. and mHoldings Trust (with certain
confidential information omitted, which omitted information is the subject
of a confidential treatment request and has been filed separately with the
Securities and Exchange Commission).*
4. Registration Rights Agreement dated as of November 26, 2001 by and among
XOMA Ltd., Millennium Pharmaceuticals, Inc. and mHoldings Trust (with
certain confidential information omitted, which omitted information is the
subject of a confidential treatment request and has been filed separately
with the Securities and Exchange Commission).*
5. Convertible Subordinated Promissory Note dated November 26, 2001 (with
certain confidential information omitted, which omitted information is the
subject of a confidential treatment request and has been filed separately
with the Securities and Exchange Commission).*
6. Letter Agreement dated May 16, 2003 by and among XOMA Ltd., Millennium
Pharmaceuticals, Inc. and mHoldings Trust.*
7. Press Release dated May 20, 2003.*
8. Letter Agreement dated February 24, 2004 by and between XOMA Ltd. and
Millennium Pharmaceuticals, Inc.*
9. Press Release dated October 12, 2004.
____________________________
* Previously filed.
-3-
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: October 12, 2004 XOMA LTD.
By: /s/ Christopher J. Margolin
---------------------------------
Christopher J. Margolin
Vice President, General
Counsel and Secretary
EXHIBIT INDEX
Number Description
------ -----------
1. Press Release dated November 26, 2001.*
2. Development and License Agreement dated as of November 26, 2001 by and
among Millennium Pharmacueticals Inc., XOMA (US) LLC and XOMA Ireland
Limited (with certain confidential information omitted, which omitted
information is the subject of a confidential treatment request and has been
filed separately with the Securities and Exchange Commission).*
3. Investment Agreement dated as of November 26, 2001 by and among XOMA Ltd.,
Millennium Pharmaceuticals, Inc. and mHoldings Trust (with certain
confidential information omitted, which omitted information is the subject
of a confidential treatment request and has been filed separately with the
Securities and Exchange Commission).*
4. Registration Rights Agreement dated as of November 26, 2001 by and among
XOMA Ltd., Millennium Pharmaceuticals, Inc. and mHoldings Trust (with
certain confidential information omitted, which omitted information is the
subject of a confidential treatment request and has been filed separately
with the Securities and Exchange Commission).*
5. Convertible Subordinated Promissory Note dated November 26, 2001 (with
certain confidential information omitted, which omitted information is the
subject of a confidential treatment request and has been filed separately
with the Securities and Exchange Commission).*
6. Letter Agreement dated May 16, 2003 by and among XOMA Ltd., Millennium
Pharmaceuticals, Inc. and mHoldings Trust.*
7. Press Release dated May 20, 2003.*
8. Letter Agreement dated February 24, 2004 by and between XOMA Ltd. and
Millennium Pharmaceuticals, Inc.*
9. Press Release dated October 12, 2004.
____________________________
* Previously filed.